Phase 2 N=43 Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
Non-Hodgkins Lymphoma
Primary: Percentage of Participants With Response — 23.3 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=45 Avastin in Combination With Docetaxel in Ovarian/Fallopian Tube/Peritoneum Carcinoma
Fallopian Tube Cancer · Ovarian Cancer · Malignant Tumor of Peritoneum
Primary: Six Month Progression Free Survival (PFS) — 43.9 percentage of participants
Phase 2 N=601 Phase 2b Study of Cetuximab With Platinum-Based Chemo as First Line Treatment of Recurrent or Advanced NSCLC
Non-Small Cell Lung Cancer
Primary: Overall Survival by Treatment Arm — 9.5; 8.3; 10.6 Months
Phase 2 N=62 Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV
Hepatitis C · HIV Infections
Primary: Proportion of Subjects Achieving Undetectable HCV RNA at Week 12 — 6; 2; 14; 2 participants
Phase 2 N=180 Photodynamic Therapy in Treating Patients With Skin Cancer
Non-melanomatous Skin Cancer · Precancerous Condition
Primary: Response Rate
Phase 2 N=17 Replagal Enzyme Replacement Therapy for Children With Fabry Disease
Fabry Disease
Primary: Patients Who Experienced At Least One Adverse Event (AE) — 17 participants
Phase 2 N=229 Arasertaconazole Nitrate Pessaries - Dose Finding Study for the Vulvovaginal Candidiasis (VVC) Treatment
Vulvovaginal Candidiasis
Primary: Dose-response of Clinical and Mycological (Global) Therapeutic Response — 31.7; 48.7; 47.6; 53.8 percentage of patients cured — p=0.0630
Phase 2 N=55 Epothilone B in Treating Patients With CNS Metastases From Breast Cancer
Breast Cancer · Metastatic Cancer
Primary: Central Nervous System (CNS) Progression-free Survival(PFS) — 12; 2 participants
Phase 2 N=81 Safety, Tolerability, and Pharmacokinetics of Iloperidone Depot in Schizophrenic Patients
Schizophrenia
Primary: Maximum Observed Plasma Concentration (Cmax) of Iloperidone Divided by the Average Plasma Concentration (Cav) of Iloperidone (Cmax/Cav) - Phase B — 1.91; 1.87 Ratio of…
Phase 2 N=35 Inhalation of Corticosteroids in Smoking and Non-smoking Asthmatics.
Asthma
Primary: Late Asthmatic Response (LAR) - Smokers: Absolute Change From Saline in Minimum Forced Expiratory Volume in One Second (FEV1) Between 4-10 Hours (Hrs) After Allergen…
Phase 2 N=12 A Pharmacokinetic And Pharmacodynamic Study Of Oral Lenalidomide (Revlimid) In Subjects With Low- Or Intermediate-1-Risk Myelodysplastic Syndromes
Low- or Intermediate-1-risk Myelodysplastic Syndrome (MDS)
Primary: PK Phase: Area-under-the Concentration-time Curve (AUC0-24) for Lenalidomide — 817 ng*h/mL
Phase 2 N=70 A Study to Assess the Pharmacokinetics of a Modified-release Tacrolimus Based Immunosuppression Regimen in Stable Liver Transplant Patients
Liver Transplantation
Primary: Area Under the Concentration-time Curve From Time 0 to 24 Hours (AUC0-24) for Tacrolimus — 215.6; 184.0; 202.4; 187.9 ng*hr/mL
Phase 2 N=82 Immune Response to Yellow Fever Vaccination in Adults With Atopic Dermatitis
Atopic Dermatitis
Primary: Comparison of Anti-YF Antibody Levels by Measurement of Log10 Neutralization Index (LNI): YFV-17D TC- (AD) Participants Compared to YFV-17D TC- (Non-AD) Participants…
Phase 2 N=50 TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV Patients
HIV Infections · Acquired Immunodeficiency Syndrome
Primary: Pharmacokinetic Results of Atazanavir (ATV): Treatment A: ATV/Low-Dose Ritonavir (Rtv) 300/100 mg (Results for C0h, Cmin, and Cmax) — 1339; 845.7; 1104; 758.6 ng/ml
Phase 2 N=61 A Study Evaluating the Effect of Botulinum Toxin Type A on Semen Quality in Patients With Benign Prostatic Hyperplasia
Benign Prostatic Hyperplasia
Primary: Percent Change in Total Sperm Count Per Ejaculate — 3.62; -12.22 Percent change